Saturday 17 October 2026
Export ALLO’s income statement to Excel — free account
Allogene Therapeutics, Inc.
ALLO Healthcare Biotechnology
Allogene Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22,000.00, down 76.8% from fiscal 2023. In the quarter to June 2026, revenue grew 20,990.9%, EPS grew 43.5% and free cash flow grew 17.7%, each against the same quarter a year earlier.
1.31
0.03
−2.24%
Follow ALLO
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | 3 | 3 | — |
P/E ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
— | — | — | — | 8.51 | 0.73 | (1.98) | (3.73) | — |
P/S ratio |
— | — | — | — | 17.76 | 5,285.44 | 5,979.93 | 4,769.53 | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | 6.45 | 0.68 | (2.92) | (7.45) | — |
P/FCF ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/Operating CF |
— | — | — | — | (44.60) | (13.28) | (10.58) | (11.31) | — |
P/B ratio |
— | — | — | — | 2.19 | 1.24 | 1.11 | 0.98 | — |
Price to Tangible BV |
— | — | — | — | 2.19 | 1.24 | 1.11 | 0.98 | — |
EV/Sales |
— | — | — | — | 13.75 | 1,969.28 | 1,256.80 | 1,407.74 | — |
EV/EBITDA |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
— | — | — | — | (8.49) | (1.39) | (0.50) | (0.61) | — |
EV/FCF |
— | — | — | — | (7.61) | (1.36) | (0.50) | (0.61) | — |
Quick Ratio |
0.00 | 15.59 | 16.04 | 8.78 | 9.55 | 9.63 | 12.10 | 8.23 | 7.70 |
Current Ratio |
0.00 | 15.89 | 16.46 | 8.96 | 9.84 | 9.84 | 12.38 | 8.54 | 7.93 |
Net Debt/EBITDA |
0.00 | 2.39 | 2.65 | 3.35 | 2.81 | 1.63 | 1.40 | 1.09 | 1.24 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.00 | 0.21 | 0.74 | 0.36 | 1.02 | 0.65 | 0.73 | 0.78 | 0.78 |
Capex/Depreciation |
0.00 | (11.49) | (35.49) | (6.09) | (1.23) | (0.30) | (0.21) | (0.13) | (0.05) |
Interest Coverage |
— | (57.43) | (11.64) | (28.18) | (105.13) | (73.49) | — | (1,509.39) | (194.71) |
| 0.00% | (60.16%) | (27.71%) | (37.03%) | (18.16%) | (42.76%) | (55.51%) | (55.13%) | (53.42%) | |
| 0.00% | (54.66%) | (24.75%) | (32.52%) | (15.98%) | (36.36%) | (44.70%) | (43.24%) | (39.58%) | |
ROIC |
0.00% | (49.44%) | (128.19%) | (64.12%) | (24.07%) | (140.22%) | (322.39%) | (131.65%) | (309.04%) |
Return on Tangible Assets |
100.00% | (47.30%) | (32.50%) | (36.38%) | (33.32%) | (57.90%) | (62.75%) | (72.78%) | (64.04%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 192.99% | 164,350.64% | 255,698.95% | 874,086.36% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 64.95% | 50,836.54% | 75,445.26% | 296,386.36% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 70.84% | 53,589.74% | 69,422.11% | 235,195.45% | 0.00% |
Graham Net Nets |
— | — | — | — | 0.17 | 0.45 | 0.58 | 0.43 | — |
Graham Number |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
— | — | — | — | (12.67%) | (40.28%) | (57.73%) | (62.44%) | — |
Free Cash Flow Yield |
— | — | — | — | (10.18%) | (27.37%) | (42.11%) | (48.44%) | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.84 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
0.00 | (1.54) | (1.36) | (0.96) | (1.36) | (1.54) | (1.51) | (1.03) | (0.68) |
Capex per Share |
0.00 | (0.18) | (0.50) | (0.55) | (0.16) | (0.04) | (0.01) | 0.00 | 0.00 |
Free Cash Flow per Share |
0.00 | (1.73) | (1.86) | (1.50) | (1.52) | (1.58) | (1.52) | (1.03) | (0.68) |
Cash per Share |
0.00 | 15.87 | 5.25 | 6.88 | 3.37 | 3.61 | 2.86 | 1.50 | 1.13 |
Shareholders Equity per Share |
0.00 | 24.29 | 6.22 | 8.97 | 6.81 | 4.66 | 3.26 | 2.17 | 1.33 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 24.29 | 6.22 | 8.97 | 6.81 | 4.66 | 3.26 | 2.17 | 1.33 |
Free Cash Flow |
0.00 | (49.98) | (188.14) | (181.05) | (206.26) | (225.71) | (239.25) | (200.99) | (149.63) |
Working Capital |
0.00 | 438.52 | 511.50 | 750.81 | 423.42 | 475.10 | 422.04 | 267.86 | 225.24 |
Capital Expenditures |
0.00 | (5.33) | (50.79) | (65.96) | (21.45) | (5.19) | (1.52) | (0.69) | (0.39) |
Net Current Asset Value |
0.00 | 397.29 | 455.80 | 696.92 | 345.70 | 374.13 | 328.51 | 176.86 | 134.39 |
EV/EBIT |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.19 | 33.28 | 15.96 | 31.55 | 0.00 |
Price to Operating Income |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.00 | 0.05 | 0.03 | 0.09 | 0.14 | 0.15 | 0.07 | 0.06 | 0.11 |
Cash ROIC |
0.00% | (4.30%) | (16.23%) | (9.49%) | (14.92%) | (19.06%) | (24.90%) | (28.12%) | (27.57%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | 25.35 | 0.03 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | 2.50 | 2.50 | 2.50 | 4.50 | 4.50 | — | — | — |
Average Payables |
— | 10.50 | 10.79 | 9.82 | 10.32 | 12.07 | 9.89 | 5.65 | 4.83 |
Average Assets |
387.00 | 386.93 | 745.83 | 972.82 | 1,139.33 | 936.20 | 732.21 | 595.77 | 482.31 |
Average Common Equity |
351.50 | 351.58 | 666.09 | 854.32 | 1,002.41 | 796.04 | 589.56 | 467.21 | 357.36 |
Columns are period end dates